Kari Grønås
Director/Board Member presso SPAGO NANOMEDICAL AB
Patrimonio netto: 4 905 $ in data 31/03/2024
Profilo
Kari Grønås currently works at Spago Nanomedical AB, as Independent Director from 2018, Ultimovacs ASA, as Director from 2019, K & K AS, as Managing Director & Director from 2012, Norwegian Cancer Society, as Director, and Arxx Therapeutics AS, as Director.
Ms. Grønås also formerly worked at Norwegian Pharmaceutical Society, as Chairman, Oncopeptides AB, as Director, Lytix Biopharma AS, as Director, BerGenBio ASA, as Independent Non-Executive Director from 2016 to 2019, SoftOx Solutions AS, as Non-Executive Director, and Algeta ASA, as Senior Vice President-Operations.
Ms. Grønås received her graduate degree from the University of Oslo.
Partecipazioni note in società pubbliche
| Società | Data | Numero di azioni | Valorizzazione | Data di valutazione |
|---|---|---|---|---|
ULTIMOVACS AS
0.02% | 31/12/2022 | 6 640 ( 0.02% ) | 4 905 $ | 31/03/2024 |
Posizioni attive di Kari Grønås
| Società | Posizione | Inizio |
|---|---|---|
| SPAGO NANOMEDICAL AB | Director/Board Member | 01/01/2018 |
| ULTIMOVACS ASA | Director/Board Member | 01/01/2019 |
K & K AS
 K & K AS Miscellaneous Commercial ServicesCommercial Services K & K AS manages securities. The company was founded on June 26, 2002 and is headquartered in Oslo, Norway. | Chief Executive Officer | 21/05/2012 |
| Norwegian Cancer Society | Director/Board Member | - |
Arxx Therapeutics AS
 Arxx Therapeutics AS BiotechnologyHealth Technology Arxx Therapeutics AS develops therapeutics for fibrotic diseases. The company is based in Oslo, Norway. The Norwegian company was founded in 2015 by Jonas Hallén, Jörg Klingelhöfer. Øystein Soug has been the CEO of the company since 2022. | Director/Board Member | - |
Precedenti posizioni note di Kari Grønås
| Società | Posizione | Fine |
|---|---|---|
| BERGENBIO ASA | Director/Board Member | 13/03/2019 |
| ONCOPEPTIDES AB | Director/Board Member | - |
| SOFTOX SOLUTIONS | Director/Board Member | - |
| Norwegian Pharmaceutical Society | Chairman | - |
| ░░░░░░ ░░░ | ░░░░░ ░░░░░░░░░ ░░░░░░░ | - |
Formazione di Kari Grønås
| University of Oslo | Graduate Degree |
Esperienze
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Relazioni
Relazioni di 1° grado
Aziende connesse in 1º grado
Uomo
Donna
Amministratori
Dirigenti
Società collegate
| Società quotate in Borsa | 6 |
|---|---|
| ONCOPEPTIDES AB | Health Technology |
| LYTIX BIOPHARMA | Health Technology |
| BERGENBIO ASA | Health Technology |
| SPAGO NANOMEDICAL AB | Health Technology |
| ULTIMOVACS ASA | Health Technology |
| SOFTOX SOLUTIONS | Commercial Services |
| Aziende private | 5 |
|---|---|
| Norwegian Pharmaceutical Society | |
K & K AS
K & K AS Miscellaneous Commercial ServicesCommercial Services K & K AS manages securities. The company was founded on June 26, 2002 and is headquartered in Oslo, Norway. | Commercial Services |
| Norwegian Cancer Society | |
Arxx Therapeutics AS
Arxx Therapeutics AS BiotechnologyHealth Technology Arxx Therapeutics AS develops therapeutics for fibrotic diseases. The company is based in Oslo, Norway. The Norwegian company was founded in 2015 by Jonas Hallén, Jörg Klingelhöfer. Øystein Soug has been the CEO of the company since 2022. | Health Technology |
Algeta ASA
 Algeta ASA Pharmaceuticals: MajorHealth Technology Algeta ASA is engaged in the development of products for the treatment of cancer. The company focuses on the development of anti-cancer drugs, and its research and development of compounds focuses on the various applications of a few base compounds. Its products, Alpharadin and Thorium-227, are being developed for treatment of skeletal metastases originating from prostate and breast cancer. The company was founded by Roy H. Larsen and Øyvind Sverre Bruland in 1997 and is headquartered in Oslo, Norway. | Health Technology |
- Borsa valori
- Insiders
- Kari Grønås
